Discovery and development of surotomycin for the treatment of Clostridium difficile (Q35869605)

10 August 2017

Discovery and development of surotomycin for the treatment of Clostridium difficile (English)

1 reference

10 August 2017

Clostridium difficile

0 references

3

Laurent Chesnel

0 references

author name string

Victoria Knight-Connoni

1

1 reference

10 August 2017

Carmela Mascio

2

1 reference

10 August 2017

Laurent Chesnel

3

1 reference

10 August 2017

Jared Silverman

4

1 reference

10 August 2017

language of work or name

1 reference

15 December 2015

1 reference

Journal of Industrial Microbiology & Biotechnology

10 August 2017

1 reference

10 August 2017

43

1 reference

10 August 2017

2-3

1 reference

10 August 2017

195-204

1 reference

Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species

10 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Effects of surotomycin on Clostridium difficile viability and toxin production in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Spore Cortex Hydrolysis Precedes Dipicolinic Acid Release during Clostridium difficile Spore Germination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Clostridium difficile drug pipeline: challenges in discovery and development of new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Burden of Clostridium difficile infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Alternative treatments for Clostridium difficile disease: what really works?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Practice parameters for the management of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1714-6

Deacylation of A21978C, an acidic lipopeptide antibiotic complex, by Actinoplanes utahensis

21 January 2018

1 reference

12 December 2020

Clostridium difficile-associated disease: new challenges from an established pathogen.

1 reference

12 December 2020

Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options

1 reference

12 December 2020

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

1 reference

12 December 2020

10.1007/S10295-015-1714-6

Identifiers

DOI

1 reference

10 August 2017

1 reference